Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Imipramine × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 3 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Cyclophosphamide 1240 Cisplatin 1182 Radiotherapy 1110 Paclitaxel 1102 Carboplatin 1046 Gemcitabine 1022 Docetaxel 958 Bevacizumab 886 Fluorouracil 745 Doxorubicin 674 Capecitabine 631 Dexamethasone 627 Rituximab 615 Oxaliplatin 584 Etoposide 564 pembrolizumab 556 Irinotecan 531 Filgrastim 530 Cytarabine 489 Leucovorin 482 Nivolumab 460 Vincristine 427 Bortezomib 407 Cetuximab 398 Prednisone 395 Erlotinib Hydrochloride 391 Trastuzumab 390 Surveys and Questionnaires 382 Methotrexate 360 Sorafenib 357

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03122444 2023-06-28

Imipramine on ER+ve and Triple Negative Breast Cancer

The University of Texas Health Science Center at San Antonio

Phase EARLY_PHASE1 Completed

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡